Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT6003 (Yttrium-90 carbon microspheres) in unresectable hepatocellular carcinoma
NCT06310590Phase 1Completed
- Sponsor
- Chengdu Newray Medical Technology
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yttrium Y 90 carbon microspheres in hepatocellular carcinoma (HCC), sponsored by Chengdu Newray Medical Technology. Primary endpoints: Adverse Events/Severe Adverse Events at 12 months and Localized Objective Response Rate at 6 months. Started Aug 2023; status: completed.
02
Drugs
yttrium Y 90 carbon microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06310590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310590.